Qiagen Gaithersburg, a wholly owned subsidiary of Qiagen and Ventana Medical Systems have agreed to a settlement of the litigation of expired patents pending between them on mutually agreeable terms.
Subscribe to our email newsletter
As part of the settlement an undisclosed cash consideration was paid by Ventana to Qiagen and Qiagen acknowledges that pursuant to an asset purchase agreement dated September 23, 2002, Ventana has lawfully succeeded to the rights of Beckman Coulter under the cross-license agreement originally entered into between Institut Pasteur and Life Technologies, effective April 1, 1990, and under the agreement between Institut Pasteur and Beckman Instruments (now Beckman Coulter), effective June 7, 1991.
The settlement was in reference to currently expired US Patent entitled “Human papillomavirus 44 nucleic acid hybridization probes and methods for employing the same” and US Patent entitled “Human papillomavirus 35 nucleic acid hybridization probes and methods for employing the same.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.